Primus Pharmaceuticals Inc.

Scottsdale, AZ, United States

Primus Pharmaceuticals Inc.

Scottsdale, AZ, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Primus Pharmaceuticals Inc. | Date: 2016-11-17

Provided is a formulation and a method associated therewith for treating inflammation. The formulation includes therapeutically effective amounts of curcuminoids and two flavonoids. The two flavonoids include baicalin and catechin.


Patent
Primus Pharmaceuticals Inc. | Date: 2016-10-14

Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as -caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.


Burnett B.P.,Primus Pharmaceuticals Inc. | Levy R.M.,Primus Pharmaceuticals Inc.
Advances in Therapy | Year: 2012

Cyclooxygenase (COX)-1, COX-2, and 5-lipoxygenase (5-LOX) enzymes produce effectors of pain and inflammation in osteoarthritis (OA) and many other diseases. All three enzymes play a key role in the metabolism of arachidonic acid (AA) to inflammatory fatty acids, which contribute to the deterioration of cartilage. AA is derived from both phospholipase A 2 (PLA 2) conversion of cell membrane phospholipids and dietary consumption of omega-6 fatty acids. Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the COX enzymes, but show no anti-5-LOX activity to prevent the formation of leukotrienes (LTs). Cysteinyl LTs, such as LTC 4, LTD 4, LTE 4, and leukoattractive LTB 4 accumulate in several organs of mammals in response to NSAID consumption. Elevated 5-LOX-mediated AA metabolism may contribute to the side-effect profile observed for NSAIDs in OA. Current therapeutics under development, so-called "dual inhibitors" of COX and 5-LOX, show improved side-effect profiles and may represent a new option in the management of OA. © 2012 Springer Healthcare.


Patent
Primus Pharmaceuticals Inc. | Date: 2010-01-26

The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2, 3, 4, 5, or 6 modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2, 3, 4, 5, or 6 modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group.


Patent
Primus Pharmaceuticals Inc. | Date: 2012-11-26

Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.


Patent
Primus Pharmaceuticals Inc. | Date: 2012-06-01

The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2, 3, 4, 5, or 6 modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2, 3, 4, 5, or 6 modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group.


Trademark
Primus Pharmaceuticals Inc. | Date: 2014-07-07

Topical creams, gels, ointments, foams and lotions for dermatological uses.


Patent
Primus Pharmaceuticals Inc. | Date: 2015-03-18

Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.


Trademark
Primus Pharmaceuticals Inc. | Date: 2015-07-20

Topical hormone preparations.


Trademark
Primus Pharmaceuticals Inc. | Date: 2015-07-20

Topical hormone preparations.

Loading Primus Pharmaceuticals Inc. collaborators
Loading Primus Pharmaceuticals Inc. collaborators